<DOC>
	<DOC>NCT00545935</DOC>
	<brief_summary>The purpose of the study is to investigate the safety and efficacy profile of a new paediatric MB formulation combined with AQ or AS and compared to AS-AQ in young African children with uncomplicated falciparum malaria.</brief_summary>
	<brief_title>Safety and Efficacy of Methylene Blue Combined With Amodiaquine or Artesunate for Malaria Treatment in Children of Burkina Faso</brief_title>
	<detailed_description />
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Amodiaquine</mesh_term>
	<mesh_term>Artesunate</mesh_term>
	<mesh_term>Artemisinins</mesh_term>
	<mesh_term>Methylene Blue</mesh_term>
	<criteria>0.55 year (659 months) old children uncomplicated malaria caused by P. falciparum asexual parasites ≥ 2000/µ and ≤ 200000/µ axillary temperature ≥ 37.5 Celsius or a history of fever during last 24 hours Burkinabe nationality informed consent complicated or severe malaria any apparent significant disease anaemia (haematocrit &lt; 21%) treated in the same trial before modern antimalarial treatment prior to inclusion (last three days), except children having been treated with chloroquine</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>59 Months</maximum_age>
	<verification_date>February 2009</verification_date>
</DOC>